Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Benzocaine, eugenol for toothache OTC "feedback" meeting with NDMA set for June 25.

This article was originally published in The Tan Sheet

Executive Summary

BENZOCAINE, EUGENOL FOR TOOTHACHE OTC "FEEDBACK" MEETING TO BE HELD at FDA June 25 with the Nonprescription Drug Manufacturers Association. In an April 29 letter to FDA, the trade association asked the agency for "feedback" on the effectiveness of both ingredients for the relief of toothache. "Our concerns to discuss at the meeting include the status of benzocaine as an active ingredient for the temporary relief of toothache when the Final Monograph for Oral Health Care Products is established," the letter states. The safety of the ingredients is not at issue.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS088410

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel